Fast-moving Caelum Biosciences Inc. said Alexion Pharmaceuticals Inc., acting to diversify its rare hematology portfolio, is betting $60 million in equity and development funding on CAEL-101 for light chain (AL) amyloidosis, also gaining an option to buy the young company if phase II data on the drug warrant for "pre-negotiated economics."